HC Wainwright 对宏碁 Therapeutics Inc. 的评论s 2023 年第一季度收益（纳斯达克股票代码：ACER）|Acer_新浪财经

Acer Therapeutics Inc. (NASDAQ:ACER – Get Rating) – Equities research analysts at HC Wainwright issued their Q1 2023 EPS estimates for shares of Acer Therapeutics in a research note issued to investors on Tuesday, March 28th. HC Wainwright analyst V. Bernardino expects that the biopharmaceutical company will post earnings of ($0.28) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $12.00 target price on the stock. The consensus estimate for Acer Therapeutics' current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Acer Therapeutics' Q3 2023 earnings at ($0.22) EPS, Q4 2023 earnings at ($0.16) EPS, FY2023 earnings at ($0.90) EPS and FY2024 earnings at ($0.18) EPS.

Get

Acer Therapeutics

alerts:

Acer Therapeutics Stock Down 1.3 %

ACER stock opened at $0.75 on Thursday. Acer Therapeutics has a 12 month low of $0.65 and a 12 month high of $4.56. The firm has a market cap of $15.80 million, a P/E ratio of -0.45 and a beta of 0.65. The company's 50-day moving average price is $1.83 and its two-hundred day moving average price is $1.83.

Institutional Investors Weigh In On Acer Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of ACER. Meridian Wealth Management LLC bought a new stake in shares of Acer Therapeutics during the 4th quarter valued at $180,000. Nantahala Capital Management LLC raised its holdings in Acer Therapeutics by 76.0% during the 4th quarter. Nantahala Capital Management LLC now owns 1,226,191 shares of the biopharmaceutical company's stock valued at $3,078,000 after buying an additional 529,653 shares during the period. Geode Capital Management LLC increased its stake in Acer Therapeutics by 6.1% in the fourth quarter. Geode Capital Management LLC now owns 96,330 shares of the biopharmaceutical company's stock worth $241,000 after purchasing an additional 5,515 shares during the period. Knott David M Jr purchased a new position in shares of Acer Therapeutics during the fourth quarter valued at $351,000. Finally, SVB Wealth LLC bought a new stake in Acer Therapeutics during the fourth quarter valued at about $29,000. 27.96% of the stock is owned by hedge funds and other institutional investors.

About Acer Therapeutics

(Get Rating)

Acer Therapeutics, Inc is a pharmaceutical company. engages in acquisition, development and commercialization of therapies for medical needs. Its product pipeline includes ACER-001 Edsivo and ACER-2820. The Edsivo is a type of celiprolol for Vascular Ehlers-Danlos syndrome. The ACER-001 is for the treatment of urea cycle disorders and Maple Syrup Urine diseases.